Ubs Asset Management Americas Inc Moon Lake Immunotherapeutics Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 43,804 shares of MLTX stock, worth $1.71 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,804
Previous 42,236
3.71%
Holding current value
$1.71 Million
Previous $2.24 Million
23.75%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding MLTX
# of Institutions
161Shares Held
55.3MCall Options Held
481KPut Options Held
229K-
Bvf Inc San Francisco, CA19.8MShares$770 Million33.91% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$331 Million35.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.97MShares$116 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$108 Million1.75% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.48MShares$57.7 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.44B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...